Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

Relapse following chimeric antigen receptor (CAR) T-cell therapy directed against CD19 for relapsed/refractory B-acute lymphoblastic leukemia (r/r B-ALL) remains a significant challenge. Three main patterns of relapse predominate: CD19 positive (CD19(pos)) relapse, CD19 negative (CD19(neg)) relapse,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamble, Adam J., Myers, Regina M., Taraseviciute, Agne, John, Samuel, Yates, Bonnie, Steinberg, Seth M., Sheppard, Jennifer, Kovach, Alexandra E., Wood, Brent, Borowitz, Michael J., Stetler-Stevenson, Maryalice, Yuan, Constance M., Pillai, Vinodh, Foley, Toni, Chung, Perry, Chen, Lee, Lee, Daniel W., Annesley, Colleen, DiNofia, Amanda, Grupp, Stephan A., Verneris, Michael R., Gore, Lia, Laetsch, Theodore W., Bhojwani, Deepa, Brown, Patrick A., Pulsipher, Michael A., Rheingold, Susan R., Gardner, Rebecca A., Shah, Nirali N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979750/
https://www.ncbi.nlm.nih.gov/pubmed/35482927
http://dx.doi.org/10.1182/bloodadvances.2022007423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979750/
https://www.ncbi.nlm.nih.gov/pubmed/35482927
http://dx.doi.org/10.1182/bloodadvances.2022007423

Ejemplares similares